Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca U.S. succession plan

Executive Summary

AstraZeneca Senior VP-U.S. Commercial Operations Tony Zook will replace U.S. President and Exec VP-North America David Brennan effective Jan. 1. Brennan has been named to succeed retiring CEO Tom McKillop (1"The Pink Sheet" Aug. 1, 2005, p. 11). Zook, who joined predecessor company Astra in 1997, previously served as AstraZeneca VP-sales; he has been leading U.S. commercial operations since Brennan was promoted to North America head in 2001 (2"The Pink Sheet" June 4, 2001, p. 32)...

You may also be interested in...



AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan

AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO

AstraZeneca

Senior VP-U.S. Commercial Operations David Brennan will become Exec VP-North America following the retirement of C.G. Johansson in July. Brennan will be succeeded by VP-Sales Tony Zook

Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel